



DuPont Central Research
and Development

ORIGINAL

(A)



8EHQ-94-13256
INIT 11/16/94

8EHQ-1194-13256

November 14, 1994

Contains No CBI

EXPRESS MAIL- RETURN RECEIPT REQUESTED

Document Processing Center (TS - 790)
Attention: 8(e) Coordinator
Office of Pollution Prevention and Toxics
U. S. Environmental Protection Agency
401 M Street SW
Washington, D.C. 20460



88950000046

NOV 16 11 03 AM '94

RECEIVED

Dear 8(e) Coordinator:

Pentafluoroethyl Iodide, CAS 354-64-3

Recently we had occasion to review a pre-1977 (1964) report on the acute inhalation toxicity of pentafluoroethyl iodide (perfluoroethyl iodide, PFEI, CAS No. 354-64-3). In four-hour inhalation exposures at 40,000 ppm, the following clinical signs in male rats were reported: incoordination, prostration with deep respiration, and semi-consciousness. The compound appeared to depress the central nervous system. Similar effects were observed, but to a lesser degree, at 20,000 ppm. Recovery from these effects occurred within one hour after exposure.

Since these observations appear to meet the criteria for substantial risk reporting, as described in EPA's June 1991 "TSCA Section 8(e) Reporting Guide", the Agency is being notified of these results. Note, however, that submission of this information is not meant to imply that DuPont considers these findings to reasonably support a conclusion that exposure to PFEI results in a substantial risk to health. Further, PFEI is a site-limited intermediate used in closed equipment in the manufacture of fluorochemicals. There are no merchant sales and hence no public exposure to this compound.

Sincerely,

Charles F. Reinhardt

Charles F. Reinhardt, M.D.
Director

CFR:dj
(302)366-5287

12/15/94



UNITED STATES ENVIRONMENTAL PROTECTION AGENCY
WASHINGTON, D.C. 20460

Mark H. Christman
Counsel
E. I. Du Pont De Nemours and Company
Legal D-7010-1
1007 Market Street
Wilmington, Delaware 19898

OFFICE OF
PREVENTION, PESTICIDES AND
TOXIC SUBSTANCES

JAN 12 1995

EPA acknowledges the receipt of information submitted by your organization under Section 8(e) of the Toxic Substances Control Act (TSCA). For your reference, copies of the first page(s) of your submission(s) are enclosed and display the TSCA §8(e) Document Control Number (e.g., 8EHQ-00-0000) assigned by EPA to your submission(s). Please cite the assigned 8(e) number when submitting follow-up or supplemental information and refer to the reverse side of this page for "EPA Information Requests".

All TSCA 8(e) submissions are placed in the public files unless confidentiality is claimed according to the procedures outlined in Part X of EPA's TSCA §8(e) policy statement (43 FR 11110, March 16, 1978). Confidential submissions received pursuant to the TSCA §8(e) Compliance Audit Program (CAP) should already contain information supporting confidentiality claims. This information is required and should be submitted if not done so previously. To substantiate claims, submit responses to the questions in the enclosure "Support Information for Confidentiality Claims". This same enclosure is used to support confidentiality claims for non-CAP submissions.

Please address any further correspondence with the Agency related to this TSCA 8(e) submission to:

Document Processing Center (7407)
Attn: TSCA Section 8(e) Coordinator
Office of Pollution Prevention and Toxics
U.S. Environmental Protection Agency
Washington, D.C. 20460-0001

EPA looks forward to continued cooperation with your organization in its ongoing efforts to evaluate and manage potential risks posed by chemicals to health and the environment.

Sincerely,

Terry R. O'Bryan

Terry R. O'Bryan
Risk Analysis Branch

Enclosure

13256 A



Recycled/Recyclable
Printed with Soy/Canola Ink on paper that
contains at least 50% recycled fiber

EPA INFORMATION REQUESTS

Document ID: ~~94-13256~~ → 94-13256

EPA requests:

1. [] No additional information at this time.
2. [] Additional information or clarification on

3. [✓] A full copy of the final report (including the actual experimental protocol, applicable results of gross or histopathologic examinations, data, results of any statistical analyses, etc.) from each study mentioned in your submission.
4. [] A description of all voluntary actions taken by your company in response to the findings indicated in your submission.
5. [] A complete copy of the current and/or revised Material Safety Data Sheets and labels for the following chemical(s) listed in your submission:

6. []

Please direct questions regarding these requests to Mr. Terry O'Bryan (202-260-3483) or Mr. John Myers (202-260-3543) of the OPPT Risk Analysis Branch.

Triage of 8(e) Submissions

Date sent to triage: APR 06 1995

NON-CAP

CAP

Submission number: 13256

TSCA Inventory: Y N D

Study type (circle appropriate):

Group 1 - Dick Clements (1 copy total)

ECO AQUATO

Group 2 - Ernie Falke (1 copy total)

ATOX SBTOX SEN **w/NEUR**

Group 3 - Elizabeth Margosches (1 copy each)

STOX CTOX EPI RTOX GTOX
STOX/ONCO CTOX/ONCO IMMUNO CYTO NEUR

Other (FATE, EXPO, MET, etc.): _____

Notes:

THIS IS THE ORIGINAL 8(e) SUBMISSION; PLEASE REFILE AFTER TRIAGE DATABASE ENTRY

		For Contractor Use Only			
entire document:	<u>0</u>	1	2	pages <u> </u>	pages <u>1</u>
Notes:					
Contractor reviewer:	<u>UPS</u>			Date:	<u>1/30/95</u>

CECATS/TRIAGE TRACKING DBASE ENTRY FORM

CECATS DATA: Submission # BEHO-1194-13256 SEQ. A

TYPE: INT: SUPP FLWP
 SUBMITTER NAME: Dept Central Research and Development

INFORMATION REQUESTED: FLWP DATE
 0501 NO INFO REQUESTED
 0502 INFO REQUESTED (TECH)
 0503 INFO REQUESTED (VOL ACTIONS)
 0504 INFO REQUESTED (REPORTING RATIONALE)
 DISPOSITION:
0639 REFER TO CHEMICAL SCREENING
 0678 CAP NOTICE

0401 VOLUNTARY ACTIONS:
 0401 NO ACTION REPORTED
 0402 STUDIES PLANNED/IN PROGRESS
 0403 NOTIFICATION OF WORKING CHANGES
 0404 LABEL/MSDS CHANGES
 0405 PROCESS/LOADING CHANGES
 0406 APP/USE DISCONTINUED
 0407 PRODUCTION DISCONTINUED
 0408 CONFIDENTIAL

SUB. DATE: 11/14/94 OTR DATE: 11/16/94 CSRAD DATE: 12/15/94

CHEMICAL NAME: _____
 CAS# 354-64-3

INFORMATION TYPE:	P F C	INFORMATION TYPE:	P F C	INFORMATION TYPE:	P F C
0201 ONCO (HUMAN)	01 02 04	0216 EPICLIN	01 02 04	0241 IMMUNO (ANIMAL)	01 02 04
0202 ONCO (ANIMAL)	01 02 04	0217 HUMAN EXPOS (PROD CONTAM)	01 02 04	0242 IMMUNO (HUMAN)	01 02 04
0203 CELL TRANS (IN VITRO)	01 02 04	0218 HUMAN EXPOS (ACCIDENTAL)	01 02 04	0243 CHEM/PHYS PROP	01 02 04
0204 MUTA (IN VITRO)	01 02 04	0219 HUMAN EXPOS (MONITORING)	01 02 04	0244 CLASTO (IN VITRO)	01 02 04
0205 MUTA (IN VIVO)	01 02 04	0220 ECO/AQUA TOX	01 02 04	0245 CLASTO (ANIMAL)	01 02 04
0206 REPRO/TERATO (HUMAN)	01 02 04	0221 ENV. OCCUR/REL/FATE	01 02 04	0246 CLASTO (HUMAN)	01 02 04
0207 REPRO/TERATO (ANIMAL)	01 02 04	0222 EMER INCI OF ENV CONTAM	01 02 04	0247 DNA DAM/REPAIR	01 02 04
0208 NEURO (HUMAN)	01 02 04	0223 RESPONSE REQEST DELAY	01 02 04	0248 PRODUCE/PROC	01 02 04
0209 NEURO (ANIMAL)	01 02 04	0224 PRODUCE/PROC	01 02 04	0251 MSDS	01 02 04
0210 ACUTE TOX. (HUMAN)	01 02 04	0225 REPORTING RATIONALE	01 02 04	0259 OTHER	01 02 04
0211 CHR. TOX (HUMAN)	01 02 04	0226 CONFIDENTIAL	01 02 04		
0212 ACUTE TOX. (ANIMAL)	01 02 04	0227 ALLERG (HUMAN)	01 02 04		
0213 SUB ACUTE TOX (ANIMAL)	01 02 04	0228 ALLERG (ANIMAL)	01 02 04		
0214 SUB CHRONIC TOX (ANIMAL)	01 02 04	0229 METAB/PHARMACO (ANIMAL)	01 02 04		
0215 CHRONIC TOX (ANIMAL)	01 02 04	0240 METAB/PHARMACO (HUMAN)	01 02 04		

TRIAGE DATA: NON-CBI INVENTORY
 YES (NO)
 CAS SR _____

ONGOING REVIEW
 YES (DROP/REFER) _____
 NO (CONTINUE) _____

SPECIES RAT
 TOXICOLOGICAL CONCERN:
LOW MED
 11K.11

USE: Site-limited intermediate
 PRODUCTION: _____

-CPSS-

> <ID NUMBER>
8(E)-13256

> <TOX CONCERN>
L

> <COMMENT>
ACUTE INHALATION TOXICITY IN MALE RATS IS OF LOW CONCERN. SINGLE
FOUR-HOUR EXPOSURES TO 20,000 AND 40,000 PPM IN RATS WERE
ASSOCIATED WITH SIGNS OF NEUROTOXICITY INCLUDING INCOORDINATION,
PROSTRATION WITH DEEP RESPIRATION AND SEMI-CONSCIOUSNESS. THERE
WERE NO DEATHS AND ANIMALS WERE RECOVERED FROM ADVERSE EFFECTS
WITHIN ONE HOUR FOLLOWING EXPOSURE.

\$\$\$\$